Abstract
Objective: To present a practical, easy-to-implement clinical framework designed to support evidence-based quality prescribing for people with early psychosis. Method: Identification and explanation of key principles relating to evidence-based pharmacotherapy for people with early psychosis. These were derived from the literature, practice guidelines and clinical experience. Results: Key principles include (1) medication choice informed by adverse effects; (2) metabolic monitoring at baseline and at regular intervals; (3) comprehensive and regular medication risk–benefit assessment and psychoeducation; (4) early consideration of long-acting injectable formulations (preferably driven by informed patient choice); (5) identification and treatment of comorbid mood disorders and (6) early consideration of clozapine when treatment refractory criteria are met. Conclusions: Current prescribing practices do not align with the well-established evidence for quality pharmacotherapy in early psychosis. Adopting evidence-based prescribing practices for people with early psychosis will improve outcomes.
| Original language | English |
|---|---|
| Pages (from-to) | 341-345 |
| Number of pages | 5 |
| Journal | Australasian Psychiatry |
| Volume | 30 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2022 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- antipsychotic medications
- early psychosis
- maintenance treatment
- prescribing practices
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver